OncoMatch/Clinical Trials/NCT05836896
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
Is NCT05836896 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies non-drug interventions for neoplasms.
The purpose of this phase I study is to determine whether MDC-CAR-BCMA001 (BCMA directed CAR T-cells) is safe and tolerable in the treatment of relapsed and refractory B-cell malignancies
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunomodulatory drug
relapsed or refractory disease after at least 2 lines of treatment including an Immunomodulatory drug
Must have received: proteasome inhibitor
relapsed or refractory disease after at least 2 lines of treatment including ... a proteasome inhibitor
Must have received: anti-CD38 antibody
relapsed or refractory disease after at least 2 lines of treatment including ... an anti-cluster of differentiation 38 antibody
Lab requirements
Blood counts
Neutrophils ≥ 0.5 Gpt/l and Platelets ≥ 50 Gpt/l (unless due to subtotal infiltration of the bone marrow by underlying malignancy); Lymphocytes ≥ 0.1 Gpt/l
Kidney function
Creatinine ≤ 1.5x Upper limit of normal
Liver function
Alaninaminotransferase and Asparataminotransferase ≤ 3.0x Upper limit of normal; Bilirubin ≤ 1.5x Upper limit of normal
Cardiac function
left ventricular ejection fraction ≥ 50%, no major valve abnormalities or dyskinesias
Adequate organ function defined as: Neutrophils ≥ 0.5 Gpt/l and Platelets ≥ 50 Gpt/l (unless due to subtotal infiltration of the bone marrow by underlying malignancy); Lymphocytes ≥ 0.1 Gpt/l; Alaninaminotransferase and Asparataminotransferase ≤ 3.0x Upper limit of normal; Bilirubin ≤ 1.5x Upper limit of normal; Creatinine ≤ 1.5x Upper limit of normal; Adequate cardiac function i.e. left ventricular ejection fraction ≥ 50%, no major valve abnormalities or dyskinesias
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05836896 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received immunomodulatory drug and proteasome inhibitor.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify